Research and Publication, IIPM Publication

While selling off its three power brands – Strepsils, Clearasil and Nurofen, seems illogical, the fact is that Boots has got a spectacular price for its sell-off, and that proves the timing for sale was excellent. While investors welcome the special dividend, Boots must now leverage its Al­liance tie-up to enhance its retail strength in Europe. Definitely a time to make the buck roll.

For More IIPM Editorial Article, Click here

Source: IIPM Editorial, 2006

Research and Publication, IIPM

Sales of dollar two billion by 2007! Doesn’t it sound a little overambitious? Especially when one sees how Ranbaxy’s strategy of concentrating on the US market seems to have backfired with profits dipping due to various reasons. Hailed as the true Indian MNC, the US market has been the cornerstone of Ranbaxy’s growth. In fact, Ranbaxy has been operating in almost all the top markets for generic drugs and more than 70% of the company’s revenues come from overseas markets. But Ranbaxy reported a dramatic 47% fall in its net profits for the quarter ended June 30. Net profits dropped from Rs.1.97 billion in the last quarter to Rs.1.01 billion.

For Detail IIPM Editorial Article, Click here

Source: IIPM Editorial, 2006

Wachovia to gobble Westcorp-IIPM News

Wachovia Corporation, one of the leading financial ser­vices providers in the US that caters to retail, brokerage and corporate customers, hasagreed to acquire California - based Westcorp, one of the largest independent automobile finance companies in the country. The deal worth $3.42 billion is expected to close in next year’s first quarter. The Westcorp acquisition will add 8,500 automobile dealer clients, close to 920,000 customers and 19 retail banking offices in Southern California, to Wachovia’s kitty…

Source: IIPM Publication

For More IIPM Editorial Article, Click here

Copyright IIPM(2006)